SeaStar Medical Reports 247% Year-Over-Year Revenue Growth in Q3 2026
SeaStar Medical Holding Corporation (ICU) reported significant top-line growth for the third quarter of 2026, with net revenue reaching $635,000. This represents a 247% increase compared to the same period last year, driven primarily by rising demand for its QUELIMMUNE therapy. The company's nine-month net revenue stands at $1.7 million, positioning it to potentially exceed its full-year guidance of $2 million. Despite the revenue surge, the company reported a net loss of $4.5 million ($1.03 per share) due to increased operating expenses, particularly in research and development for the NEUTRALIZE-AKI study. Management also provided an updated timeline for clinical trials, noting that enrollment is 75% complete with expected completion by midyear 2027. While the extended timeline was noted as a point of disappointment, recent survival data from the SAVE Registry showed statistically significant improvements in patient outcomes.
Topics: clinical trials financial guidance net loss revenue growth